The small size of the US Food and Drug Administration advisory committee that weighed Eisai Co., Ltd. and Biogen, Inc.’s Alzheimer’s treatment Leqembi (lecanemab-irmb) for conversion from accelerated to regular approval seems to have highlighted some gaps in the agency’s conflict-of-interest screening and disclosure process.
A December 2022 letter signed by hundreds of Alzheimer’s disease researchers and clinicians precluded “several potential experts” from participating on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?